Carolyn Rekerdres, MD
Psychiatry · Dallas, TXNPI 1104020346
Payments from drug & device makers
Across 395 payments — averaging $654.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$232K
- AbbVie$25K
- Teva Pharmaceuticals USA, Inc.$522
- Alkermes, Inc.$331
- E.r. Squibb & Sons, L.L.C.$212
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$209
- plus $305 from 4 others
What the payments were for
- Consulting fees$6,6603%
- Speaking & faculty fees$198,17377%
- Travel & lodging$45,99818%
- Food & beverage$7,6033%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 258 | $231,974 |
| AbbVie(2 entities) | 44 | $24,992 |
| Teva Pharmaceuticals USA, Inc. | 28 | $522 |
| Alkermes, Inc. | 19 | $331 |
| E.r. Squibb & Sons, L.L.C. | 25 | $212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $209 |
| Neurocrine Biosciences, Inc. | 6 | $169 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Indivior Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$229,255
- INVEGA TRINZA$217,712
- VRAYLAR$24,242
- INVEGA$419
- SPRAVATO$129
- AUSTEDO$101
How this compares
$258,545 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 16 | $127,005 |
| Austedo XrDeutetrabenazine | 16 | $100,178 |
| Invega SustennaPaliperidone Palmitate | 20 | $59,064 |
| UzedyRisperidone | 15 | $40,817 |
| RexultiBrexpiprazole | 23 | $31,488 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $30,261 |
| CaplytaLumateperone Tosylate | 12 | $21,322 |
| VraylarCariprazine Hcl | 14 | $20,299 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $12,631 |
| Lurasidone Hcl | 28 | $9,848 |
| Varenicline Tartrate | 24 | $5,349 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 17 | $3,932 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $2,401 |
| Haloperidol Decanoate | 27 | $1,756 |
| Trazodone Hcl | 110 | $1,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $231,974 | $186,07036 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $522 | $140,99531 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $68 | $31,48823 claims |
| Alkermes, Inc.Lybalvi | $331 | $30,26121 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $209 | $21,32212 claims |
| AbbVieVraylar | $24,992 | $20,29914 claims |
| Axsome Therapeutics, Inc.Auvelity | $20 | $12,63114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.